NASDAQ:ALNYAlnylam Pharmaceuticals Stock Price, Forecast & News

Alnylam Pharmaceuticals' stock was trading at $101.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALNY shares have increased by 53.5% and is now trading at $156.41. View which stocks have been most impacted by Coronavirus.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($1.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.89) by $0.27. The biopharmaceutical company had revenue of $71.94 million for the quarter, compared to analysts' expectations of $90.45 million. Alnylam Pharmaceuticals had a negative return on equity of 57.63% and a negative net margin of 310.01%. The company's quarterly revenue was up 173.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.42) EPS. View Alnylam Pharmaceuticals' earnings history.

18 brokers have issued 12 month target prices for Alnylam Pharmaceuticals' stock. Their forecasts range from $74.00 to $202.00. On average, they expect Alnylam Pharmaceuticals' share price to reach $153.33 in the next year. This suggests that the stock has a possible downside of 2.0%. View analysts' price targets for Alnylam Pharmaceuticals.

News articles about ALNY stock have trended positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news about Alnylam Pharmaceuticals.

Some companies that are related to Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), Opko Health (OPK), AbbVie (ABBV) and Vertex Pharmaceuticals (VRTX).

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Alnylam Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.03%), International Biotechnology Trust PLC (0.03%), State of Alaska Department of Revenue (0.02%), DNB Asset Management AS (0.01%), IFM Investors Pty Ltd (0.01%) and New England Research & Management Inc. (0.00%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Philip A Sharp, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet. View institutional ownership trends for Alnylam Pharmaceuticals.

ALNY stock was sold by a variety of institutional investors in the last quarter, including IFM Investors Pty Ltd. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Phillip A Sharp, Steven M Paul, and Yvonne Greenstreet. View insider buying and selling activity for Alnylam Pharmaceuticals.

ALNY stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., State of Alaska Department of Revenue, International Biotechnology Trust PLC, New England Research & Management Inc., DNB Asset Management AS, Sanders Morris Harris LLC, Exchange Traded Concepts LLC, and IBM Retirement Fund. View insider buying and selling activity for Alnylam Pharmaceuticals.

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALNY stock can currently be purchased for approximately $156.41.

Alnylam Pharmaceuticals has a market capitalization of $18.04 billion and generates $219.75 million in revenue each year. The biopharmaceutical company earns $-886,120,000.00 in net income (profit) each year or ($8.11) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,323 workers across the globe.

The official website for Alnylam Pharmaceuticals is www.alnylam.com.

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]